Literature DB >> 27320045

Fibrate therapy and flow-mediated dilation: A systematic review and meta-analysis of randomized placebo-controlled trials.

Amirhossein Sahebkar1, Renato Giua2, Claudio Pedone3, Kausik K Ray4, Antonio J Vallejo-Vaz4, Luisa Costanzo3.   

Abstract

Flow-mediated dilation (FMD) of the brachial artery reflects endothelium-dependent vasodilator function; since it correlates with coronary endothelial function, its reduction could predict cardiovascular events. Several studies have investigated the potential impact of fibrates therapy on endothelial function, but clinical findings have not been fully consistent. We aimed to conduct a meta-analysis of randomized placebo-controlled trials in order to clarify whether fibrate therapy could improve endothelial function. A systematic search in PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases was performed to identify randomized placebo-controlled trials investigating the effect of fibrates on endothelial function as estimated by FMD. A random-effects model and generic inverse variance method were used for meta-analysis. Sensitivity analysis, risk of bias evaluation, and publication bias assessment were carried out using standard methods. Random-effects meta-regression was used to evaluate the impact of treatment duration on the estimated effect size. Fifteen trials with a total of 556 subjects met the eligibility criteria. Fibrate therapy significantly improves FMD (weighted mean difference [WMD]: 1.64%, 95% CI: 1.15, 2.13, p<0.001) and the result was confirmed in both subgroups with treatment durations ≤8 weeks (WMD: 1.35%, 95% CI: 0.85, 1.86, p<0.001) and >8 weeks (WMD: 2.55%, 95% CI: 1.21, 3.89, p<0.001). When the analysis was stratified according to the fibrate type, a significant effect was observed with fenofibrate but not with gemfibrozil, though difference between the two subgroups was not significant. Meta-analysis of data from trials where nitrate mediated dilation (NMD) was available did not suggest a significant change in NMD following treatment with fibrates. The results of this meta-analysis suggest that fibrates may exert beneficial effects on endothelial function, even over a short-term treatment course.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cardiovascular risk; Endothelial function; Flow-mediated dilation; Meta-analysis; Pharmacology

Mesh:

Substances:

Year:  2016        PMID: 27320045     DOI: 10.1016/j.phrs.2016.06.011

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  3 in total

1.  Optimizing Lipid Pattern by Adding a Combined Nutraceutical or Pravastatin to Fenofibrate Treatment in Hypertriglyceridemic Subjects: Single Site, Randomized, Open-Label, Post-Market Clinical Investigation.

Authors:  Arrigo F G Cicero; Federica Fogacci; Marilisa Bove; Fulvio Ventura; Marina Giovannini; Claudio Borghi
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-09-18

2.  Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials.

Authors:  Amirhossein Sahebkar; Luis E Simental-Mendía; Niki Katsiki; Željko Reiner; Maciej Banach; Matteo Pirro; Stephen L Atkin
Journal:  BMJ Open       Date:  2019-02-22       Impact factor: 2.692

3.  Lipid Parameters are Independently Associated with Cardio-Ankle Vascular Index (CAVI) in Healthy Japanese Subjects.

Authors:  Daiji Nagayama; Yasuhiro Watanabe; Atsuhito Saiki; Kohji Shirai; Ichiro Tatsuno
Journal:  J Atheroscler Thromb       Date:  2018-01-12       Impact factor: 4.928

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.